Literature DB >> 21794264

[Cost analysis in a cohort of rheumatoid arthritis patients managed in rheumatology units in Spain].

M D Ruiz-Montesinos1, B Hernández-Cruz, R Ariza-Ariza, L Carmona, J Ballina, F Navarro-Sarabia.   

Abstract

OBJECTIVE: To assess the annual costs of rheumatoid arthritis (RA) patients attended at rheumatology units in Spanish public hospitals.
METHODS: A longitudinal, prospective, multicenter, observational, 1-year study was performed in the rheumatology units of randomly selected Spanish public hospitals. Randomly selected RA patients were included. The patients made four visits (at baseline and every 4 months). Resource use and costs were collected from patient diaries and structured questionnaires.
RESULTS: A total of 301 patients were included and 190 (83% women) completed the study. The mean (± SD) age was 59±13 years and the mean disease duration was 10±10 years. The median annual cost per patient was 3,845 euros (318-36,783). The estimated total annual cost of the Spanish RA population managed in the rheumatology units of public hospitals was 590,110,000 euros. Of total costs, 74% were direct costs and 26% were indirect costs. Medical costs represented 81% of direct costs. The main components of medical costs were drugs (56%), medical visits (21%), complementary tests (12%), and hospitalizations (11%). Permanent work disability represented 66% of indirect costs.
CONCLUSIONS: Direct costs were substantially higher than indirect costs. The main components of medical costs were drugs. There was high variability in resource use with a wide range of annual costs per patient.
Copyright © 2005 Elsevier España S.L. Barcelona. Published by Elsevier Espana. All rights reserved.

Entities:  

Year:  2008        PMID: 21794264     DOI: 10.1016/S1699-258X(05)72744-3

Source DB:  PubMed          Journal:  Reumatol Clin        ISSN: 1699-258X


  5 in total

1.  Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry.

Authors:  M Cárdenas; S de la Fuente; M C Castro-Villegas; M Romero-Gómez; D Ruiz-Vílchez; J Calvo-Gutiérrez; A Escudero-Contreras; J R Del Prado; E Collantes-Estévez; P Font
Journal:  Rheumatol Int       Date:  2016-10-24       Impact factor: 2.631

2.  Variability in the frequency of rheumatology consultations in patients with rheumatoid arthritis in Spain.

Authors:  R Lopez-Gonzalez; D Seoane-Mato; S Perez-Vicente; M A Martin-Martinez; F Sanchez-Alonso; L Silva-Fernandez
Journal:  Rheumatol Int       Date:  2016-08-18       Impact factor: 2.631

3.  Clinical and therapeutic management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: RADAR study.

Authors:  Antonio Gomez-Centeno; Esteban Rubio-Romero; Juan Gabriel Ovalles; Sara Manrique-Arija; Sara Marsal-Barril; Juan Amarelo-Ramos; Javier Del Pino-Montes; Santiago Muñoz-Fernández; Sagrario Bustabad; Ceferino Barbazán-Álvarez
Journal:  Rheumatol Int       Date:  2019-08-08       Impact factor: 2.631

4.  Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry.

Authors:  M Cárdenas; S de la Fuente; P Font; M C Castro-Villegas; M Romero-Gómez; D Ruiz-Vílchez; J Calvo-Gutiérez; A Escudero-Contreras; M A Casado; J R Del Prado; E Collantes-Estévez
Journal:  Rheumatol Int       Date:  2016-02       Impact factor: 2.631

5.  Hospitalization burden and comorbidities of patients with rheumatoid arthritis in Spain during the period 2002-2017.

Authors:  Mario Gil-Conesa; Juan Antonio Del-Moral-Luque; Ruth Gil-Prieto; Ángel Gil-de-Miguel; Ramón Mazzuccheli-Esteban; Gil Rodríguez-Caravaca
Journal:  BMC Health Serv Res       Date:  2020-05-04       Impact factor: 2.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.